75 research outputs found

    Evaluation of a new airborne microwave remote sensing radiometer by measuring the salinity gradients across the shelf of the Great Barrier Reef lagoon

    Get PDF
    Over the last ten years, some operational airborne remote sensing systems have become available for mapping surface salinity over large areas in near real time. A new dual-polarized Polarimetric L-band Multibeam Radiometer (PLMR) has been developed to improve accuracy and precision when compared with previous instrument generations. This paper reports on the first field evaluation of the performance of the PLMR by measuring salinity gradients in the central Great Barrier Reef. Before calibration, the raw salinity values of the PLMR and conductivity-temperature-depth (CTD) differed by 3-6 psu. The calibration, which uses in situ salinity data to remove long-term drifts in the PLMR as well as environmental effects such as surface roughness and radiation from the sky and atmosphere, was carried out by equating the means of the PLMR and CTD salinity data over a subsection of the transect, after which 85% of the salinity values between the PLMR and CTD are within 0.1 psu along the complete transect. From offshore to inshore across the shelf, the PLMR shows an average cross-shelf salinity increase of about 0.4 psu and a decrease of 2 psu over the inshore 20 km at -19deg S (around Townsville) and -18deg S (around Lucinda), respectively. The average cross-shelf salinity increase was 0.3 psu for the offshore 100 km over all transects. These results are consistent with the in situ CTD results. This survey shows that PLMR provided an effective method of rapidly measuring the surface salinity in near real time when a calibration could be made

    Merkel Cell Polyomavirus DNA in Respiratory Specimens from Children and Adults

    Get PDF
    Merkel cell polyomavirus (MCPyV) DNA was detected in 7 (1.3%) of 526 respiratory tract samples from patients in Australia with upper or lower respiratory tract symptoms. Partial T antigen and major capsid protein sequences of MCPyV identified in respiratory secretions showed high homology (99%–100%) to those found in Merkel cell carcinoma

    Detection and management of milk allergy:Delphi consensus study

    Get PDF
    Background: There is significant overdiagnosis of milk allergy in young children in some countries, leading to unnecessary use of specialized formula. This guidance, developed by experts without commercial ties to the formula industry, aims to reduce milk allergy overdiagnosis and support carers of children with suspected milk allergy.Methods: Delphi study involving two rounds of anonymous consensus building and an open meeting between January and July 2021. Seventeen experts in general practice, nutrition, midwifery, health visiting, lactation support and relevant areas of paediatrics participated, located in Europe, North America, Middle East, Africa, Australia and Asia. Five authors of previous milk allergy guidelines and seven parents provided feedback.Findings: Participants agreed on 38 essential recommendations through consensus. Recommendations highlighted the importance of reproducibility and specificity for diagnosing milk allergy in children with acute or delayed symptoms temporally related to milk protein ingestion; and distinguished between children directly consuming milk protein and exclusively breastfed infants. Consensus was reached that maternal dietary restriction is not usually necessary to manage milk allergy, and that for exclusively breastfed infants with chronic symptoms, milk allergy diagnosis should only be considered in specific, rare circumstances. Consensus was reached that milk allergy diagnosis does not need to be considered for stool changes, aversive feeding or occasional spots of blood in stool, if there is no temporal relationship with milk protein ingestion. When compared with previous guidelines, these consensus recommendations resulted in more restrictive criteria for detecting milk allergy and a more limited role for maternal dietary exclusions and specialized formula.Interpretation: These new milk allergy recommendations from non-conflicted, multidisciplinary experts advise narrower criteria, more prominent support for breastfeeding and less use of specialized formula, compared with current guidelines.</p

    Practicality, Validity and Responsiveness of Using the Proxy Version of the CHU-9D with Children Aged 2 to 5 Years

    Get PDF
    Objectives To assess the practicality, validity and responsiveness of proxy CHU-9D in children aged 2-5 years. Methods We used data from BEEP, a UK randomised controlled trial testing whether daily emollients in infancy could prevent eczema in high-risk infants. The main parent/carer completed the proxy CHU-9D using developers’ additional guidance for completion in under-5’s and the Patient-Orientated Eczema Measure (POEM) at ages 2, 3, 4 and 5. Practicality was assessed by completion rates. Construct validity assessed if CHU-9D could discriminate between those with/without eczema and between eczema severity levels on POEM. Responsiveness was determined by ability to discriminate between three groups: those whose POEM score, i) deteriorated ≥3 points, ii) change not clinically important (-2.9 to 2.9 points), and iii) improved ≥3 points. Analysis was conducted in STATA 17. Results Of 1,394 children participating in BEEP, study questionnaires were completed by 1,212 (87%), 981 (70%), 990 (71%), and 976 (70%) at 2, 3, 4 and 5-years. Of these the CHU-9D was completed by 1,066 (88.0%), 685 (69.8%), 925 (93.4%) and 923 (94.6%) respectively. Mean utility at all timepoints was around 0.934 (range 0.443-1). For construct validity, very small differences on the CHU-9D between known groups were observed(p <0.01). 801 participants had responsiveness data: 13% deteriorated, 72% had non-clinically important change, and 15% improved. Mean utility change (standardised response mean) for these groups was -0.0198 (0.21), 0.0041 (0.05), and 0.0175 (0.21)showing small change and small responsiveness. Conclusions Proxy CHU-9D in 2-5 year old children shows potential but further research is needed

    Emollients for preventing atopic eczema: Cost‐effectiveness analysis of the BEEP trial

    Get PDF
    BackgroundRecent discoveries have led to the suggestion that enhancing skin barrier from birth might prevent eczema and food allergy. ObjectiveTo determine the cost‐effectiveness of daily all‐over‐body application of emollient during the first year of life for preventing atopic eczema in high‐risk children at 2 years from a health service perspective. We also considered a 5‐year time horizon as a sensitivity analysis. MethodsA within‐trial economic evaluation using data on health resource use and quality of life captured as part of the BEEP trial alongside the trial data. Parents/carers of 1394 infants born to families at high risk of atopic disease were randomised 1:1 to the emollient group, which were advised to apply emollient (Doublebase Gel or Diprobase Cream) to their child at least once daily to the whole body during the first year of life or usual care. Both groups received advice on general skin care. The main economic outcomes were incremental cost‐effectiveness ratio (ICER), defined as incremental cost per percentage decrease in risk of eczema in the primary cost‐effectiveness analysis. Secondary analysis, undertaken as a cost‐utility analysis, reports incremental cost per Quality‐Adjusted Life Year (QALY) where child utility was elicited using the proxy CHU‐9D at 2 years. ResultsAt 2 years, the adjusted incremental cost was £87.45 (95% CI −54.31, 229.27) per participant, whilst the adjusted proportion without eczema was 0.0164 (95% CI −0.0329, 0.0656). The ICER was £5337 per percentage decrease in risk of eczema. Adjusted incremental QALYs were very slightly improved in the emollient group, 0.0010 (95% CI −0.0069, 0.0089). At 5 years, adjusted incremental costs were lower for the emollient group, −£106.89 (95% CI −354.66, 140.88) and the proportion without eczema was −0.0329 (95% CI −0.0659, 0.0002). The 5‐year ICER was £3201 per percentage decrease in risk of eczema. However, when inpatient costs due to wheezing were excluded, incremental costs were lower and incremental effects greater in the usual care group. ConclusionsIn line with effectiveness endpoints, advice given in the BEEP trial to apply daily emollient during infancy for eczema prevention in high‐risk children does not appear cost‐effective

    Central Burma Depression and Its Petroleum Occurrences

    Full text link
    corecore